NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

TAL Education Group (NYSE: TAL)
Class Period: April 26, 2018 to June 13, 2018
Lead Plaintiff Deadline: August 17, 2018

The lawsuit alleges that throughout the class period, TAL Education Group made materially false and/or misleading statements and/or failed to disclose that: (1) the Company overstated its net income; (2) the Company's net income was deteriorating; and (3) as a result of the foregoing, Defendants' statements about TAL's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the TAL lawsuit: http://www.kleinstocklaw.com/pslra-c/tal-education-group?wire=3

QUALCOMM Incorporated (NASDAQ: QCOM)
Class Period: January 31, 2018 to March 12, 2018
Lead Plaintiff Deadline: August 7, 2018

During the class period, QUALCOMM Incorporated allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Qualcomm had secretly filed a unilateral notice with CFIUS in order to frustrate Broadcom's attempt to acquire the Company; and (2) investors suffered damages as a result of defendants' wrongful acts and omissions.    

On March 5, 2018, Broadcom announced that Qualcomm had filed a voluntary request for The Committee on Foreign Investment in the United States to initiate an investigation into Broadcom’s actions. Broadcom referred to this as a “blatant, desperate act by Qualcomm to entrench its incumbent board of directors and prevent its own stockholders from voting for Broadcom’s independent director nominees.”

Get additional information about the QCOM lawsuit: http://www.kleinstocklaw.com/pslra-c/qualcomm-incorporated?wire=3

REV Group, Inc. (NYSE: REVG)
Class Period: Pursuant to the January 27, 2017 IPO and between January 27, 2017 and June 7, 2018
Lead Plaintiff Deadline: August 7, 2018

The lawsuit alleges REV Group, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company was experiencing cost inflation across many of the commodities and services it bought; (2) the Company was experiencing difficulty obtaining the chassis necessary for production; (3) the Company’s margins were being negatively impacted by a lower sales of high margin products; (4) the Company did not have “strong visibility into future net sales” to “effectively plan” and manage its backlog of vehicles; (5) the Company’s manufacturing operations were not operating efficiently or at a low cost to satisfy customer demand; (6) and as a result of the foregoing, Defendants’ statements about REV’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the REVG lawsuit: http://www.kleinstocklaw.com/pslra-c/rev-group-inc?wire=3

Flex Pharma, Inc. (NASDAQ: FLKS)
Class Period: November 6, 2017 to June 12, 2018
Lead Plaintiff Deadline: August 20, 2018

According to the complaint, Flex Pharma, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and (ii) as a result, Flex's public statements were materially false and misleading at all relevant times.

On June 13, 2018, Flex announced that it planned to halt its FLX-787 trials, citing oral tolerability concerns observed in both studies. Flex also said that it will restructure its organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic alternatives, including the potential sale or merger of the company." Following this news, Flex stock dropped $3.14 per share, or 75.12%, to close at $1.04 on June 13, 2018.

Get additional information about the FLKS lawsuit: http://www.kleinstocklaw.com/pslra-c/flex-pharma-inc?wire=3

Recro Pharma, Inc. (NASDAQ: REPH)
Class Period: July 31, 2017 to May 23, 2018
Lead Plaintiff Deadline: July 30, 2018

The complaint alleges that throughout the class period Recro Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration ("FDA") approval; and (2) as a result, Recro Pharma's public statements were materially false and misleading at all relevant times.

On May 24, 2018, Recro Pharma announced that the FDA had declined to approve its New Drug Application ("NDA") for IV meloxicam. In its Complete Response Letter, the FDA stated that the drug's analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data.

Get additional information about the REPH lawsuit: http://www.kleinstocklaw.com/pslra-c/recro-pharma-inc-2?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com